erythropoietin beta
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aneurysmal Subarachnoid Hemorrhage
Conditions
Aneurysmal Subarachnoid Hemorrhage
Trial Timeline
Apr 1, 2005 → Mar 1, 2007
NCT ID
NCT00140010About erythropoietin beta
erythropoietin beta is a phase 2 stage product being developed by Roche for Aneurysmal Subarachnoid Hemorrhage. The current trial status is completed. This product is registered under clinical trial identifier NCT00140010. Target conditions include Aneurysmal Subarachnoid Hemorrhage.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00140010 | Phase 2 | Completed |
Competing Products
8 competing products in Aneurysmal Subarachnoid Hemorrhage
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Denosumab | Amgen | Phase 2 | 51 |
| Clazosentan + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan | Idorsia | Phase 2 | 47 |
| Clazosentan 5 m/h + Clazosentan 15 mg/h + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan 1 mg/h + Clazosentan 5 mg/h + Clazosentan 15 mg/h + Placebo | Idorsia | Phase 2 | 47 |
| GTX-104 + Nimodipine Capsules | Grace Therapeutics | Phase 1 | 25 |
| GTX-104 + Nimotop 30 MG Oral Capsule | Grace Therapeutics | Phase 3 | 69 |